[{"NetIncomeLoss_2_Q2_USD":-108658000.0,"FairValueLiabilitiesLevel2ToLevel1TransfersAmount_0_Q2_USD":0.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":13605000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":17216000.0,"AssetsCurrent_0_Q2_USD":364229000.0,"OperatingLeaseExpense_2_Q2_USD":6700000.0,"OperatingLeaseExpense_1_Q2_USD":5300000.0,"LongTermDebtCurrent_0_Q2_USD":11250000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_Q2_USD":171861000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":27758000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":2207000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":16098000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2_Q2_USD":-171000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q2_USD":-72000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":422220000.0,"Assets_0_Q2_USD":564302000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-72000.0,"ShareBasedCompensation_2_Q2_USD":12354000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":83006000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"ConvertibleDebtFairValueDisclosures_0_Q2_USD":310700000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-22000.0,"LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0_Q2_USD":163434000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":22394000.0,"LongTermDebtFairValue_0_Q2_USD":46800000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":236798000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2_Q2_USD":197584000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":3034000.0,"AccountsReceivableNetCurrent_0_Q2_USD":2701000.0,"CommonStockValue_0_Q2_USD":72000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0_Q2_USD":18249000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":1080000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":-421000.0,"DeferredRevenueNoncurrent_0_Q2_USD":87000000.0,"FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_2_Q2_USD":0.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":128895000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-108829000.0,"OtherAssetsNoncurrent_0_Q2_USD":6453000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":37154000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":1117403000.0,"Liabilities_0_Q2_USD":547813000.0,"OperatingLeaseLiability_0_Q2_USD":107903000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":36795000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":21197000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":71476.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":71754.0,"CommitmentsAndContingencies_0_Q2_USD":0.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-61626000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":17668000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":5581000.0,"IncreaseDecreaseInAccountsPayableTrade_2_Q2_USD":-2380000.0,"AmortizationOfFinancingCosts_1_Q2_USD":29000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":7093000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-59015000.0,"ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_2_Q2_USD":3300000.0,"LiabilitiesCurrent_0_Q2_USD":61766000.0,"AccountsPayableCurrent_0_Q2_USD":14928000.0,"NonoperatingIncomeExpense_2_Q2_USD":477000.0,"NonoperatingIncomeExpense_1_Q2_USD":187000.0,"InterestExpense_2_Q2_USD":8061000.0,"InterestExpense_1_Q2_USD":4073000.0,"FairValueLiabilitiesLevel1ToLevel2TransfersAmount_0_Q2_USD":0.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":11227000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":2694000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.098,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":37154000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q2_USD":969000.0,"FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_2_Q2_USD":0.0,"OperatingLeasePayments_2_Q2_USD":2600000.0,"DebtSecuritiesAvailableForSaleGainLoss_2_Q2_USD":0.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":9258000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":36942000.0,"NetIncomeLoss_1_Q2_USD":-61554000.0,"LongTermDebtNoncurrent_0_Q2_USD":35538000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":36443000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":-1719000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-1100964000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":9391000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":2843000.0,"OperatingIncomeLoss_2_Q2_USD":-95408000.0,"OperatingIncomeLoss_1_Q2_USD":-54797000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":313147000.0,"AvailableForSaleSecuritiesNoncurrent_0_Q2_USD":73672000.0,"InvestmentIncomeInterest_2_Q2_USD":500000.0,"InvestmentIncomeInterest_1_Q2_USD":200000.0,"PreferredStockValue_0_Q2_USD":0.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":564302000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-45831000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":8779000.0,"OperatingExpenses_2_Q2_USD":104799000.0,"OperatingExpenses_1_Q2_USD":57640000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":83208000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.52,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.86,"ProfitLoss_2_Q2_USD":-108658000.0,"OtherLiabilitiesCurrent_0_Q2_USD":1004000.0,"StockholdersEquity_0_Q2_USD":16489000.0,"PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_0_Q2_USD":4133000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":15418000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":12190000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":68004000.0,"Ticker":"CYTK","CIK":"1061983","name":"CYTOKINETICS INC","OfficialName":"Cytokinetics Incorporated Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"2","uom":"USD","footnote":"nan","Market Cap":"3243164482.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210806"}]